The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Apogee Therapeutics Inc | COM | 03770N101 | 44,050 | 583,591 | SH | SOLE | 583,591 | 0 | 0 | |||
| Spyre Therapeutics Inc | COM | 00773J202 | 47,706 | 1,456,231 | SH | SOLE | 1,456,231 | 0 | 0 | |||
| Oruka Therapeutics Inc | COM | 687604108 | 47,054 | 1,552,414 | SH | SOLE | 1,552,414 | 0 | 0 | |||
| Jade Biosciences Inc | COM | 008064206 | 24,345 | 1,577,750 | SH | SOLE | 1,577,750 | 0 | 0 | |||
| Crescent Biopharma Inc | COM | 38000Q201 | 4,284 | 361,250 | SH | SOLE | 361,250 | 0 | 0 | |||
| Galecto Inc | COM | 36322Q206 | 2,772 | 120,473 | SH | SOLE | 120,473 | 0 | 0 | |||